Effects of Framing on Medication Beliefs, Intentions to Take Medication, Adherence, and Asthma Control

• Sponsor: Auburn University (Other)
• Overall Status: Completed
• CT.gov ID: NCT06033313
• Collaborator: (none)
• Enrollment: 43
• Location: 1
• Arms: 2
• Actual Duration (Months): 2
• Patients Per Site Per Month: 21.8

Study Details

Study Description

Brief Summary

The goal of this study is to examine the effects of framed mobile messages on young adults' beliefs about their daily Inhaled Corticosteroids (ICS), intentions to take their ICS, adherence, and asthma control. College students (18-29 years) who owned a mobile phone and had a diagnosis of asthma with a prescription for an ICS will be recruited. Participants will be randomized to receive either gain- or loss-framed mobile messages three times per week for eight weeks. Outcomes including beliefs, intentions, adherence, and asthma control will be assessed.

Condition or Disease	Intervention/Treatment	Phase
Asthma	Behavioral: Negatively Framed text messages; Behavioral: Positively Framed text messages	N/A

Study Design

• Study Type: Interventional
• Actual Enrollment: 43 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Participant)
• Primary Purpose: Supportive Care
• Official Title: Examining the Effect of Message Framing on Medication Beliefs, Intentions to Take Medications, Adherence to Medication, and Asthma Control Among College Students
• Actual Study Start Date: Oct 1, 2019
• Actual Primary Completion Date: Nov 30, 2019
• Actual Study Completion Date: Nov 30, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Positively framed text messages Positively framed text messages	Behavioral: Positively Framed text messages; Positively Framed text messages delivered to participants three times per week for 8 weeks.
Experimental: Negatively frame text messages Negatively framed text messages	Behavioral: Negatively Framed text messages; Negatively Framed text messages delivered to participants three times per week for 8 weeks.

Outcome Measures

Primary Outcome Measures

1. Changes in Asthma control [Data collection at baseline, week 4, and week 8]

   Asthma control as measured by the Asthma Control Test (minimum value=5, maximum value= 25) Questionnaire (scores of 20 and above indicate asthma control)

Secondary Outcome Measures

1. Changes in Medication Beliefs [Data collection at baseline and week 8]

   Medication Beliefs as measured by the Beliefs about Medicines Questionnaire-Specific (This scale has two sub-scales : necessity (20- points) and concerns (20 points). A difference of necessity and concern scores shows the level of perceived necessity for the medication. Higher scores indicate higher perceived necessity for the medication.

2. Intentions to take medication as prescribed [Data collection at baseline and week 8]

   Intentions to take inhaled corticosteroids as prescribed as measured by an intentions scale (minimum score = 3, maximum score = 15; higher scores indicate greater intentions; the scale was tested in the study)

3. Changes in Medication adherence [Data collection at baseline, week 4, and week 8]

   Adherence to a daily dose of inhaled corticosteroid as measured by the Medication Adherence Report Scale for Asthma (MARS-A) (Minimum score = 10, maximum score = 50, higher scores indicate greater adherence)

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 29 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• A diagnosis of asthma

• A prescription for an inhaled corticosteroid

• Enrolled in college

• Between 18-29 years of age

• Owns a mobile phone

Exclusion Criteria:

• Cannot read in english

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Auburn University	Auburn	Alabama	United States	36849

Sponsors and Collaborators

• Auburn University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Ruth Jeminiwa, Principal Investigator, Auburn University
• ClinicalTrials.gov Identifier: NCT06033313
• Other Study ID Numbers: 19-221
• First Posted: Sep 13, 2023
• Last Update Posted: Sep 13, 2023
• Last Verified: Sep 1, 2023

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Ruth Jeminiwa, Principal Investigator, Auburn University: mHealth; message framing
• Additional relevant MeSH terms: Asthma

Study Results

No Results Posted as of Sep 13, 2023